Revelation Biosciences (REVB) Expected to Announce Earnings on Friday

Revelation Biosciences (NASDAQ:REVB – Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of ($0.83) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Revelation Biosciences (NASDAQ:REVB – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($2.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($1.56). On average, analysts expect Revelation Biosciences to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Get Revelation Biosciences alerts:

Revelation Biosciences Stock Up 10.8%

Shares of NASDAQ REVB opened at $1.13 on Wednesday. The firm’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.31. Revelation Biosciences has a 52-week low of $0.88 and a 52-week high of $11.72. The company has a market cap of $4.42 million, a PE ratio of -0.03 and a beta of -0.15.

Institutional Trading of Revelation Biosciences

A hedge fund recently bought a new position in Revelation Biosciences stock. Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 2.15% of Revelation Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Check Out Our Latest Report on REVB

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.

Featured Stories

• Five stocks we like better than Revelation Biosciences
• System Upgrade: First Internet Bancorp Options Surge
• AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
• The AI Chip Blockade Is Creating a Shadow Market
• Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.